GlassScriptPhysician profile
Karen E Gil
NPI 1679180533
$1,659.38
in general payments reported to CMS, 2019-2025
12 companies · $120 in 2025
The $120 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $364 · 2023: $1,084 · 2024: $91.89 · 2025: $120.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,296.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,295.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $538.77 | 2023-2025 | Repatha, Otezla, Otezla |
| E.R. Squibb & Sons, L.L.C. | $238.29 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $162.16 | 2022-2023 | Imfinzi, Tagrisso |
| Glaxosmithkline, LLC. | $137.42 | 2023 | Arexvy, Zejula, Jemperli |
| Seagen INC. | $113.41 | 2022-2023 | Padcev, Adcetris |
| Incyte Corporation | $105.37 | 2022-2023 | Monjuvi, Pemazyre, Jakafi |
| Taiho Oncology, INC. | $97.08 | 2023-2024 | |
| Regeneron Healthcare Solutions, INC. | $77.51 | 2023 | Libtayo |
| Janssen Biotech, INC. | $67.64 | 2023-2024 | Akeega, Balversa, Erleada |
| Shield Therapeutics INC | $48.41 | 2025 | |
| Jazz Pharmaceuticals INC. | $36.69 | 2023 | |
| Emd Serono, INC. | $36.63 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karen Gil listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.